New drug combo aims to wipe out hidden myeloma cells

NCT ID NCT06910124

Recruiting now Disease control Sponsor: Dickran Kazandjian, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding linvoseltamab to standard lenalidomide maintenance can eliminate remaining cancer cells in people with multiple myeloma. About 32 participants will receive the combination for up to 24 cycles. The goal is to see if this approach can deepen remission or bring back a no-cancer-cell state after relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: linvoseltamab and lenalidomide
What this could lead to: If successful, this combination could help more multiple myeloma patients achieve a deep remission with no detectable cancer cells, potentially delaying relapse.
What could go wrong: This is a small, early-phase trial (32 participants) with no control group, so results may not apply broadly. Linvoseltamab can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.